search
Back to results

The Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Oesophageal Pain Hypersensitivity

Primary Purpose

Esophageal Diseases

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Transcutaneous vagal nerve stimulation
Sponsored by
Wingate Institute of Neurogastroenterology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Esophageal Diseases

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Ability to provide Informed written consent
  • Healthy volunteers aged 18-65, who have no medical history

Exclusion Criteria:

  • Any inclusion criteria not met
  • Subjects unable to provide informed consent.
  • Subjects with any systemic disease or medications that may influence the autonomic nervous system (e.g. beta-agonists or Parkinson's disease).
  • Pregnant females to prevent any confounding effects on pregnancy related nausea.
  • Subjects who suffer from reflux disease
  • Subject who take any medication, including over the counter preparations

Sites / Locations

  • Wingate Institute of NeurogastroenterologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Transcutaneous vagal nerve stimulation

Sham vagal nerve stimulation

Arm Description

Active vagal nerve stimulation to the left auricular branch of the vagus nerve.

Placebo vagal nerve stimulation stimulation. The stimulator is attached to the left ear, but rotated 180 degrees, so that it is not stimulating the auricular branch of the vagal nerve.

Outcomes

Primary Outcome Measures

Sensitisation to electrical stimuli in the proximal oesophagus following a distal oesophageal acid infusion in comparison to baseline
Pain tolerance thresholds to electrical stimulation in the proximal oesophagus decrease following a distal oesophageal acid infusion due to central sensitisation and are defined as a reduction of >6mA in thresholds. Prevention of sensitisation will be defined as this threshold not being met.

Secondary Outcome Measures

Sensitisation to electrical stimuli in the proximal oesophagus following a distal oesophageal acid infusion in comparison to baseline
Pain tolerance thresholds to electrical stimulation in the proximal oesophagus decrease following a distal oesophageal acid infusion due to central sensitisation and are defined as a reduction of >6mA in thresholds. Prevention of sensitisation will be defined as this threshold not being met.
Sensitisation to electrical stimuli in the proximal oesophagus following a distal oesophageal acid infusion in comparison to baseline
Pain tolerance thresholds to electrical stimulation in the proximal oesophagus decrease following a distal oesophageal acid infusion due to central sensitisation and are defined as a reduction of >6mA in thresholds. Prevention of sensitisation will be defined as this threshold not being met.
Effect of vagal nerve stimulation on cardiac vagal tone during stimulation in comparison to baseline
The effect of vagal stimulation on the validated parameter of cardiac vagal tone
Effect of vagal nerve stimulation on cardiac sympathetic index during stimulation in comparison to baseline
The effect of vagal stimulation on the validated parameter of cardiac sympathetic index.

Full Information

First Posted
December 15, 2014
Last Updated
November 28, 2015
Sponsor
Wingate Institute of Neurogastroenterology
search

1. Study Identification

Unique Protocol Identification Number
NCT02620176
Brief Title
The Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Oesophageal Pain Hypersensitivity
Official Title
The Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Oesophageal Pain Hypersensitivity in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
November 2015
Overall Recruitment Status
Unknown status
Study Start Date
December 2014 (undefined)
Primary Completion Date
February 2016 (Anticipated)
Study Completion Date
February 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Wingate Institute of Neurogastroenterology

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
We are evaluating the role of transcutaneous electrical vagal nerve stimulation in the prevention of oesophageal pain hypersensitivity using a validated human model in healthy volunteers.
Detailed Description
Chronic oesophageal pain is a symptomatic feature of disorders such as erosive oesophagitis, non-erosive reflux disease and non-cardiac chest pain. Patients often display heightened sensitivity to intra-oesophageal stimuli, which is referred to as oesophageal pain hypersensitivity. However, the experience of oesophageal pain is highly individual with a multitude of factors proposed to account for this variability. Amongst the physiological factors is the autonomic nervous system (ANS). The ANS has been postulated to play a pivotal role in the modulation of pain through its multiple interactions with pain processing. The ANS has two broadly antithetic branches, the parasympathetic nervous system (PNS) and the sympathetic nervous system (SNS). The primary neural substrate of the PNS is the vagus nerve. The vagus nerve is increasingly considered to play an integral role in modulating oesophageal pain. Electrical vagal nerve stimulation (VNS) was first used in humans in 1988 and is an efficacious treatment for drug resistant epilepsy. Traditional VNS is undertaken in a procedure where a bipolar helical electrode is placed around the cervical vagal nerve, which is connected to a pulse generator placed in subcutaneous pocket in the chest, not dissimilar to a cardiac pacemaker. However, this method of VNS necessitates surgical implantation with its attendant risks and complications. Recently, an external transcutaneous VNS (t-VNS) system, consisting of an earplug-like electrode to interface with the concha of the outer ear and a handheld battery-powered electrical stimulator, has become commercially available (NEMOS system). The auricular branch of the vagus nerve innervates the concha of the ear and is located directly under the skin, making it a suitable target for transcutaneous stimulation. t-VNS has been demonstrated to be safe, well tolerated and have a high degree of user-friendliness. A preliminary study has reported that t-VNS reduces sensitivity to heat pain in healthy volunteers. Furthermore, recent studies have demonstrated that t-VNS patterns of cerebral activation, as determined by functional magnetic resonance imaging, were similar to those evoked by traditional VNS. Thus, VNS per se represents an attractive proposition for investigating the role of the PNS in oesophageal pain and t-VNS specifically, a viable, safe and acceptable technology for achieving this. The pivotal experiments evaluating the analgesic role of VNS in the development of acid induced oesophageal pain hypersensitivity have not been conducted. Using the aforementioned model of oesophageal pain hypersensitivity, we seek to determine the analgesic effect of t-VNS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Transcutaneous vagal nerve stimulation
Arm Type
Experimental
Arm Description
Active vagal nerve stimulation to the left auricular branch of the vagus nerve.
Arm Title
Sham vagal nerve stimulation
Arm Type
Placebo Comparator
Arm Description
Placebo vagal nerve stimulation stimulation. The stimulator is attached to the left ear, but rotated 180 degrees, so that it is not stimulating the auricular branch of the vagal nerve.
Intervention Type
Device
Intervention Name(s)
Transcutaneous vagal nerve stimulation
Other Intervention Name(s)
NEMOS
Intervention Description
Trans-auricular vagal nerve stimulation
Primary Outcome Measure Information:
Title
Sensitisation to electrical stimuli in the proximal oesophagus following a distal oesophageal acid infusion in comparison to baseline
Description
Pain tolerance thresholds to electrical stimulation in the proximal oesophagus decrease following a distal oesophageal acid infusion due to central sensitisation and are defined as a reduction of >6mA in thresholds. Prevention of sensitisation will be defined as this threshold not being met.
Time Frame
90 minutes post acid infusion
Secondary Outcome Measure Information:
Title
Sensitisation to electrical stimuli in the proximal oesophagus following a distal oesophageal acid infusion in comparison to baseline
Description
Pain tolerance thresholds to electrical stimulation in the proximal oesophagus decrease following a distal oesophageal acid infusion due to central sensitisation and are defined as a reduction of >6mA in thresholds. Prevention of sensitisation will be defined as this threshold not being met.
Time Frame
30 minutes post acid infusion
Title
Sensitisation to electrical stimuli in the proximal oesophagus following a distal oesophageal acid infusion in comparison to baseline
Description
Pain tolerance thresholds to electrical stimulation in the proximal oesophagus decrease following a distal oesophageal acid infusion due to central sensitisation and are defined as a reduction of >6mA in thresholds. Prevention of sensitisation will be defined as this threshold not being met.
Time Frame
60 minutes post acid infusion
Title
Effect of vagal nerve stimulation on cardiac vagal tone during stimulation in comparison to baseline
Description
The effect of vagal stimulation on the validated parameter of cardiac vagal tone
Time Frame
30 minutes
Title
Effect of vagal nerve stimulation on cardiac sympathetic index during stimulation in comparison to baseline
Description
The effect of vagal stimulation on the validated parameter of cardiac sympathetic index.
Time Frame
30 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Ability to provide Informed written consent Healthy volunteers aged 18-65, who have no medical history Exclusion Criteria: Any inclusion criteria not met Subjects unable to provide informed consent. Subjects with any systemic disease or medications that may influence the autonomic nervous system (e.g. beta-agonists or Parkinson's disease). Pregnant females to prevent any confounding effects on pregnancy related nausea. Subjects who suffer from reflux disease Subject who take any medication, including over the counter preparations
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Adam D Farmer, PhD MRCP
Phone
02088822640
Email
a.farmer@qmul.ac.uk
Facility Information:
Facility Name
Wingate Institute of Neurogastroenterology
City
London
ZIP/Postal Code
E1 @AJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ADam Farmer, PhD MRCP
Phone
+442078822640
Email
a.farmer@qmul.ac.uk
First Name & Middle Initial & Last Name & Degree
Susan Surguy, PhD
Phone
+442078822645
Email
s.surguy@qmul.ac.uk

12. IPD Sharing Statement

Citations:
PubMed Identifier
24870622
Citation
Botha C, Farmer AD, Nilsson M, Brock C, Gavrila AD, Drewes AM, Knowles CH, Aziz Q. Preliminary report: modulation of parasympathetic nervous system tone influences oesophageal pain hypersensitivity. Gut. 2015 Apr;64(4):611-7. doi: 10.1136/gutjnl-2013-306698. Epub 2014 May 28.
Results Reference
background
Links:
URL
http://www.cerbomed.com
Description
Description: Vagal nerve stimulator information

Learn more about this trial

The Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Oesophageal Pain Hypersensitivity

We'll reach out to this number within 24 hrs